Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Sezary Syndrome 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Primary Myelofibrosis 1

Interventions

rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1MEDI0457 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anal Canal Carcinoma × Immunoglobulin G × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡